Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959970 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
A Phase 4 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT02959970 is a Phase 4 study that has completed, run by Almirall, S.A.. The registered enrollment target is 100 participants.
The verdict
NCT02959970, a Phase 4 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
Interventions
- DRUG dapsone gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2018-03-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02959970
The ClinicalTrials.gov registry entry for NCT02959970 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dapsone gel is the first listed.
NCT02959970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02959970 about?
NCT02959970 is a clinical study titled "Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris". This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
What is the current status of trial NCT02959970?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2016-10-31. Estimated completion is 2018-03-09.
What interventions are being tested in trial NCT02959970?
The interventions under investigation include: dapsone gel (DRUG).
Who is sponsoring clinical trial NCT02959970?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.